Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release

Ryan T Hurt,1–4 Manpreet S Mundi,3 Jon O Ebbert5 1Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA; 2Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA; 3Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, M...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hurt RT, Mundi MS, Ebbert JO
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Lorcaserin Belviq Obese Pharmacotherapy Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/30bc9e7e93e84bcfac4840001f22ecfc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:30bc9e7e93e84bcfac4840001f22ecfc
record_format	dspace
spelling	oai:doaj.org-article:30bc9e7e93e84bcfac4840001f22ecfc2021-12-02T00:33:02ZChallenging obesity, diabetes, and addiction: the potential of lorcaserin extended release1178-7007https://doaj.org/article/30bc9e7e93e84bcfac4840001f22ecfc2018-09-01T00:00:00Zhttps://www.dovepress.com/challenging-obesity-diabetes-and-addiction-the-potential-of-lorcaserin-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Ryan T Hurt,1–4 Manpreet S Mundi,3 Jon O Ebbert5 1Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA; 2Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA; 3Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, MN, USA; 4Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, USA; 5Division of Primary Care Internal Medicine, Mayo Clinic, Rochester, MN, USA Abstract: Obesity is a global epidemic that is a leading cause of preventable death. In addition to lifestyle modification, there are numerous obesity treatments for clinicians to consider, including medications. Lorcaserin immediate release/extended release (IR/XR) is a US Food and Drug Administration approved medication for overweight and obese patients to be used with lifestyle modifications. Lorcaserin is thought to reduce weight by targeting the serotonin (5HT2c) system to induce satiety. Lorcaserin IR has been shown to be effective in reducing weight in overweight (body mass index [BMI] > 27 kg/m2) and obese (BMI > 30 kg/m2) participants in three large Phase III trials. In addition, lorcaserin has been shown to reduce post-cessation weight gain and improved smoking cessation in a randomized placebo-controlled trial. A recent meta-analysis suggested in overweight diabetic patients lorcaserin may be added to first-line oral hypoglycemic medications to enhance reduction in glycated hemoglobin. Lorcaserin is generally well tolerated with the most common side effect being headache, which is typically self-limiting. Lorcaserin XR (once daily) was recently approved and has been shown to be bioequivalent to lorcaserin IR (twice daily) in a pivotal study. Lorcaserin XRs, main advantage over the IR formulation is the once daily dosing regimen, which likely would lead to improved adherence and thus improved clinical effectiveness. The present review will evaluate the lorcaserin clinical studies (obesity, diabetes, and addiction), XR bioequivalence studies, pharmacogenomics of the serotonin (5HT2c) system, and adherence data in once daily versus twice daily medications. Keywords: lorcaserin, Belviq©, obese, pharmacotherapyHurt RTMundi MSEbbert JODove Medical PressarticleLorcaserinBelviqObesePharmacotherapySpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 11, Pp 469-478 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Lorcaserin Belviq Obese Pharmacotherapy Specialties of internal medicine RC581-951
spellingShingle	Lorcaserin Belviq Obese Pharmacotherapy Specialties of internal medicine RC581-951 Hurt RT Mundi MS Ebbert JO Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
description	Ryan T Hurt,1–4 Manpreet S Mundi,3 Jon O Ebbert5 1Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA; 2Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA; 3Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, MN, USA; 4Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, USA; 5Division of Primary Care Internal Medicine, Mayo Clinic, Rochester, MN, USA Abstract: Obesity is a global epidemic that is a leading cause of preventable death. In addition to lifestyle modification, there are numerous obesity treatments for clinicians to consider, including medications. Lorcaserin immediate release/extended release (IR/XR) is a US Food and Drug Administration approved medication for overweight and obese patients to be used with lifestyle modifications. Lorcaserin is thought to reduce weight by targeting the serotonin (5HT2c) system to induce satiety. Lorcaserin IR has been shown to be effective in reducing weight in overweight (body mass index [BMI] > 27 kg/m2) and obese (BMI > 30 kg/m2) participants in three large Phase III trials. In addition, lorcaserin has been shown to reduce post-cessation weight gain and improved smoking cessation in a randomized placebo-controlled trial. A recent meta-analysis suggested in overweight diabetic patients lorcaserin may be added to first-line oral hypoglycemic medications to enhance reduction in glycated hemoglobin. Lorcaserin is generally well tolerated with the most common side effect being headache, which is typically self-limiting. Lorcaserin XR (once daily) was recently approved and has been shown to be bioequivalent to lorcaserin IR (twice daily) in a pivotal study. Lorcaserin XRs, main advantage over the IR formulation is the once daily dosing regimen, which likely would lead to improved adherence and thus improved clinical effectiveness. The present review will evaluate the lorcaserin clinical studies (obesity, diabetes, and addiction), XR bioequivalence studies, pharmacogenomics of the serotonin (5HT2c) system, and adherence data in once daily versus twice daily medications. Keywords: lorcaserin, Belviq©, obese, pharmacotherapy
format	article
author	Hurt RT Mundi MS Ebbert JO
author_facet	Hurt RT Mundi MS Ebbert JO
author_sort	Hurt RT
title	Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
title_short	Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
title_full	Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
title_fullStr	Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
title_full_unstemmed	Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
title_sort	challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/30bc9e7e93e84bcfac4840001f22ecfc
work_keys_str_mv	AT hurtrt challengingobesitydiabetesandaddictionthepotentialoflorcaserinextendedrelease AT mundims challengingobesitydiabetesandaddictionthepotentialoflorcaserinextendedrelease AT ebbertjo challengingobesitydiabetesandaddictionthepotentialoflorcaserinextendedrelease
_version_	1718403667453804544

Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release

Ejemplares similares